RA Capital Management Increases Stake in Artiva Biotherapeutics

RA Capital Management boosted its investment in Artiva Biotherapeutics, Inc. (NasdaqGM:ARTV) by purchasing 124,893 shares on June 16, 2026. The shares were bought at an average price of $8.89, totaling approximately $1.11 million.

What Changed in RA Capital Management's Artiva Biotherapeutics Position

RA Capital Management's recent purchase of 124,893 shares of Artiva Biotherapeutics, valued at about $1.11 million, marks a significant addition to their holdings. The shares were acquired at an average price of $8.89 each, reflecting RA Capital's continued confidence in the company's prospects.

Other Institutional Activity in Artiva Biotherapeutics

Several other institutional investors have positions in Artiva Biotherapeutics. RA Capital Management, L.P. holds a substantial total of 9,853,302 shares valued at around $63.46 million. Meanwhile, 5AM Venture Management, LLC maintains 2,353,304 shares worth about $15.16 million. Venrock Adviser, LLC holds 1,609,569 shares valued at approximately $10.37 million. Venbio Partners LLC reduced its holdings by 117,170 shares, bringing its total to 531,337 shares worth $3.42 million.

Artiva Biotherapeutics Stock Snapshot

Shares of Artiva Biotherapeutics, Inc. (NasdaqGM:ARTV) traded near $9.18. The company, with a market capitalization of around $414.9 million, has a 52-week range between $1.47 and $14.53. Artiva's forward P/E ratio is not meaningful as the company is not currently profitable. Its 50-day moving average is $9.04, and its 200-day moving average is $5.33. The company maintains a strong liquidity position with a current ratio of 8.16 and a quick ratio of 7.98, alongside a debt-to-equity ratio of 11.68.

Insider Buying and Selling at Artiva Biotherapeutics, Inc.

RA Capital Management has been an active buyer of Artiva Biotherapeutics shares. On June 16, 2026, they purchased 124,893 shares at $8.89 each. This follows a series of buys earlier in June, including 15,414 shares on June 15 at $8.99, 391,019 shares on June 12 at $8.57, and 548,580 shares on June 11 at $7.91.

Analysts Set New Price Targets

Analysts remain bullish on Artiva Biotherapeutics. On June 8, 2026, Needham reiterated its buy rating with a price target of $41.00. Previously, on May 11, both Cantor Fitzgerald and Wedbush maintained their buy ratings with targets of $40.00. HC Wainwright & Co. also maintained a buy rating with a $35.00 target on May 8. Overall, the stock has a consensus rating of "strong buy" with an average price target of $35.80 from five analysts.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc. is a biotechnology company based in San Diego, California. It focuses on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company's lead product is AlloNK, an off-the-shelf NK cell therapy targeting diseases such as rheumatoid arthritis and various cancers. Artiva is also developing other NK cell products for solid tumors and hematological malignancies. Founded in 2019, the company is led by CEO Dr. Fred Aslan and employs 104 people.

Bottom Line

RA Capital Management's recent purchase of Artiva Biotherapeutics shares signals confidence in the company's future. Investors often track such insider transactions as potential indicators of company prospects. These purchases, however, are historical and may not reflect current positions. Artiva, with its innovative therapies, continues to attract attention from analysts and investors alike.